Imlunestrant - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Imlunestrant

Brand Name:

Inluriyo

Strength:

200mg

HCPCS:

N/A

SEER*Rx Category:

Hormonal Therapy

Major Drug Class:

Estrogen Receptor Antagonist

Minor Drug Class:

ER⍺

Oral (Y/N):

Yes

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use